Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.
Phase 2
- Conditions
- Age-Related Macular Degeneration
- Registration Number
- NCT00148551
- Lead Sponsor
- Canadian Retinal Trials Group
- Brief Summary
A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT therapy in conjunction with intravitreal triamcinolone.
- Detailed Description
This study will evaluate the effect of Triamcinolone Acetonide in conjunction with photodynamic therapy for the treatment of sub-foveal choroidal neovascular membranes secondary to age-related macular degeneration.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
- Individuals with predominantly classic, subfoveal CNV secondary to AMD.
- No previous PDT Treatment in study eye.
Exclusion Criteria
- CNV from conditions, other than AMD.
- Other disease that could be responsible for decreased vision.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Changes in visual acuity from baseline.
- Secondary Outcome Measures
Name Time Method Change in lesion characteristics from baseline.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does intravitreal triamcinolone acetonide synergize with VPDT in neovascular ARMD (NCT00148551, Phase 2, Canadian Retinal Trials Group)?
What is the comparative efficacy of triamcinolone acetonide plus VPDT versus anti-VEGF monotherapy in subfoveal choroidal neovascularization?
Which inflammatory biomarkers correlate with treatment response in NCT00148551 triamcinolone acetonide and VPDT combination therapy for ARMD?
What long-term adverse events were observed in NCT00148551 using intravitreal triamcinolone acetonide for neovascular ARMD and how were they managed?
Are there alternative corticosteroids or combination therapies with anti-VEGF agents for subfoveal choroidal neovascular membranes in ARMD?
Trial Locations
- Locations (1)
Eye Care Centre
🇨🇦Vancouver, British Columbia, Canada